Pharma & biotech

Novo Nordisk to focus more on the US: Europe is already ten years behind

Uncertainty in Europe, and a booming life science environment in Boston, means that Novo Nordisk is now focusing investments in the US. ”That’s simply where it’s happening,” the CEO tells MedWatch.
"You will see that Novo Nordisk putting a lot of effort into the investments in Boston," says Lars Fruergaard Jørgensen, CEO of Novo Nordisk. (Archive) | Photo: Novo Nordisk / Pr
"You will see that Novo Nordisk putting a lot of effort into the investments in Boston," says Lars Fruergaard Jørgensen, CEO of Novo Nordisk. (Archive) | Photo: Novo Nordisk / Pr
BY PETER THOMSEN, WATCH MEDIA’s EU CORRESPONDENT

The growth in the US biotech hub, coupled with uncertainty and ailing conditions in the EU, means that Novo Nordisk will increasingly turn its attention away from Europe and across the Atlantic in the coming years, says its CEO, Lars Fruergaard Jørgensen, in an interview with MedWatch.

”We will never leave Denmark, but we will invest relatively more in the US than we do in Europe,” asserts Fruergaard Jørgensen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs